Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 8, 2008, Pages 1109-1116

  Stephan, Sina ^a   Schwarz, Herbert ^a   Borchert, Anja ^a   Bussfeld, Delia ^a   Quak, Elfriede ^a   Simshaeuser Knaub, Beate ^a   Teigelkamp, Stefan ^a   Behrens, Fritz ^a   Vitzthum, Frank ^a  

^a SIEMENS AG   (Germany)

Author keywords

Cardiovascular disease; Factor VII activating protease (FSAP); Hemostasis; Marburg I polymorphism; Prourokinase

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7 ACTIVATING PROTEASE; CITRIC ACID; PROUROKINASE; SERINE PROTEINASE;

ANTIGEN DETECTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL LABORATORY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENOTYPE; HEMOSTASIS; HUMAN; LABORATORY TEST; MEASUREMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE MARBURG I POLYMOPRHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM;

ANTIGENS; BLOOD CHEMICAL ANALYSIS; COSTS AND COST ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; TIME FACTORS;

EID: 50249109626     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.218     Document Type: Article

References (33)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
2. World Health Organisation. The World health report (annex). Available at www.who.int/whr/2004/en/index.html. Accessed 2008.
3. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107:9-16.
4. Vitzthum F, Behrens F, Anderson NL, Shaw JH. Proteomics: from basic research to diagnostic application. A review of requirements and needs. J Proteome Res 2005;4:1086-97.
5. Gundry RL, Van Eyk JE. Unraveling the complexity of circulating forms of brain natriuretic peptide. Clin Chem 2007;53:1181-2.
6. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
7. Willeit J, Kiechl S, Weimer T, Mair A, Santer P, Wiedermann CJ, et al. Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003;107:667-70.
8. Ireland H, Miller GJ, Webb KE, Cooper JA, Humphries SE. The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. Thromb Haemost 2004;92:986-92.
9. Weisbach V, Ruppel R, Eckstein R. The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism. Thromb Haemost 2007;97:870-2.
10. Hoppe B, Tolou F, Dorner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost 2006;96:465-70.
11. Hoppe B, Dorner T, Kiesewetter H, Salama A. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:907-8; author reply:908.
12. Gulesserian T, Hron G, Endler G, Eichinger S, Wagner O, Kyrle PA. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:65-7.
13. Franchi F, Martinelli I, Biguzzi E, Bucciarelli P, Mannucci PM. Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood 2006;107:1731.
14. van Minkelen R, de Visser MC, Vos HL, Bertina RM, Rosendaal FR. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005;105:4898; author reply:4899.
15. Hoppe B, Tolou F, Radtke H, Kiesewetter H, Dorner T, Salama A. Association of Marburg I polymorphism of factor VII-activating protease with venous thromboembolism is limited to idiopathic events. Blood 2005;105:4899.
16. Hoppe B, Tolou F, Radtke H, Kiesewetter H, Dorner T, Salama A. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005;105:1549-51.
17. Choi-Miura NH, Tobe T, Sumiya J, Nakano Y, Sano Y, Mazda T, et al. Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem (Tokyo) 1996;119:1157-65.
18. Kannemeier C, Feussner A, Stohr HA, Weisse J, Preissner KT, Roemisch J. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 2001;268:3789-96.
19. Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U, et al. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 2005;385:831-8.
20. Choi-Miura NH, Saito K, Takahashi K, Yoda M, Tomita M. Regulation mechanism of the serine protease activity of plasma hyaluronan binding protein. Biol Pharm Bull 2001;24:221-5.
21. Roemisch J, Feussner A, Vermohlen S, Stohr HA. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinol 1999;10:471-9.
22. Roemisch J, Vermohlen S, Feussner A, Stohr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999;29:292-9.
23. Kannemeier C, Al-Fakhri N, Preissner KT, Kanse SM. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004;18:728-30.
24. Kanse SM, Parahuleva M, Muhl L, Kemkes-Matthes B, Sedding D, Preissner KT. Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost 2008;99:286-9.
25. Sedding D, Daniel JM, Muhl L, Hersemeyer K, Brunsch H, Kemkes-Matthes B, et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 2006;203:2801-7.
26. Parahuleva MS, Kanse SM, Parviz B, Barth A, Tillmanns H, Bohle RM, et al. Factor seven activating protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques. Atherosclerosis 2007;196:164-71.
27. Etscheid M, Beer N, Kress JA, Seitz R, Dodt J. Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur J Cell Biol 2004;82:597-604.
28. Roemisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002;383:1119-24.
29. Roemisch J, Feussner A, Stohr HA. Quantitation of the factor VII- and single-chain plasminogen activator-activating protease in plasmas of healthy subjects. Blood Coagul Fibrinol 2001;12:375-83.
30. Roemisch J, Feussner A, Nerlich C, Stoehr HA, Weimer T. The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinol 2002;13:433-41.
31. Dade Behring Inc. Standard human plasma for the calibration of coagulation and fibrinolysis tests. Product insert sheet, product code number ORKL 13 or 21, 2003.
32. Roemisch J, Feussner A, Stoehr HA. Procedure for the detection of the activity of the protease which activates factor VII from protein solutions. 2003: US Patent Application Publication 2003/0124622 A1.
33. Schumann G, Aoki R, Ferrero CA, Ehlers G, Ferard G, Gella FJ, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): Scientific Division, Committee on Reference Systems for Enzymes (C-RSE): Part 8. Reference procedure for the measurement of catalytic concentration of α-amylase: [α-amylase: 1,4-α-D-glucan 4-glucanohydrolase (AMY), EC 3.2.1.1]. Clin Chem Lab Med 2006;44:1146-55.